1 October 2018 in Nature Genetics
GCGlobal Lipids Genetics Consortium
Global Lipids Genetics Consortium
MCMyocardial Infarction Genetics (MIGen) Consortium
Myocardial Infarction Genetics (MIGen) Consortium
TCThe Geisinger-Regeneron DiscovEHR Collaboration
The Geisinger-Regeneron DiscovEHR Collaboration
TPThe Va Million Veteran Program
The Va Million Veteran Program
+43
15 February 2005 in Spinal Cord
Study design: Prospective mortality study. Objective: To assess the relationship between comorbid medical conditions and other health-related factors to mortality in chronic spinal cord injury (SCI). Setting: Boston, MA, USA. Methods: Between 1994 and 2000, 361 males ⩾1 year after injury completed a respiratory health questionnaire and underwent pulmonary function testing. Cause-specific mortality was assessed over a median of 55.6 months (range 0.33–74.4 months) through 12/31/2000 using the National Death Index. Results: At entry, mean (±SD) age was 50.6±15.0 years (range 23–87) and years since injury was 17.5±12.8 years (range 1.0–56.5). Mortality was elevated (observed/expected deaths=37/25.1; SMR=1.47; 95% CI=1.04–2.03) compared to US rates. Risk factors for death were diabetes (RR=2.62; 95% CI=1.19–5.77), heart disease (RR=3.66; 95% CI=1.77–7.78), reduced pulmonary function, and smoking. The most common underlying and contributing causes of death were diseases of the circulatory system (ICD-9 390–459) in 40%, and of the respiratory system in 24% (ICD-9 460-519). Conclusions: These results suggest that much of the excess mortality in chronic SCI is related to potentially treatable factors. Recognition and treatment of cardiovascular disease, diabetes, and lung disease, together with smoking cessation may substantially reduce mortality in chronic SCI.
1 February 2004 in Ophthalmology
5 January 2011 in BMC Medical Research Methodology
Previous studies have proposed a simple product-based estimator for calculating exposure-specific risks (ESR), but the methodology has not been rigorously evaluated. The goal of our study was to evaluate the existing methodology for calculating the ESR, propose an improved point estimator, and propose variance estimates that will allow the calculation of confidence intervals (CIs).
1 May 2000 in The American Journal of Clinical Nutrition
Background: Vitamin K has been associated with bone mineral density (BMD) and risk of hip fracture. The apolipoprotein (apo) E4 allele (APOE*E4) has been associated with bone fracture through a putative effect on vitamin K transport in blood. Objective: The objective was to determine the associations between vitamin K intake, apo E genotype, BMD, and hip fracture in a population-based cohort of elderly men and women. Design: Dietary vitamin K intake was assessed with a food-frequency questionnaire in 335 men and 553 women (average age: 75.2 y) participating in the Framingham Heart Study in 1988–1989. Incidence of hip fractures was recorded from 1988 to 1995. BMD at the hip, spine, and arm was assessed on 2 separate occasions (1988–1989 and 1992–1993). Comparisons between apo E genotype and BMD were made relative to E4 allele status (at least 1 ϵ4 allele compared with no ϵ4 allele). Results: Individuals in the highest quartile of vitamin K intake (median: 254 μg/d) had a significantly lower fully adjusted relative risk (0.35; 95% CI: 0.13, 0.94) of hip fracture than did those in the lowest quartile of intake (median: 56 μg/d). There were no associations between vitamin K intake and BMD in either men or women. No association was found between the E4 allele and BMD, and there were no significant interactions between the E4 allele and phylloquinone intake and BMD or hip fracture. Conclusions: Low vitamin K intakes were associated with an increased incidence of hip fractures in this cohort of elderly men and women. Neither low vitamin K intake nor E4 allele status was associated with low BMD.
1 March 1994 in American Heart Journal